We’ve reviewed the available evidence on myostatin antagonists and muscle mass, and what we’ve found so far leans toward the idea that blocking myostatin is associated with increased muscle mass in both humans and animals [1]. This conclusion is based on six assertions that support this observation, with no studies or claims in the current dataset contradicting it. Myostatin is a protein that naturally limits muscle growth. When its activity is reduced—through drugs, gene changes, or other methods—muscle tissue tends to grow larger in animal models and some human trials. These findings come from studies where myostatin was blocked either genetically or pharmacologically, and muscle size was measured afterward. The pattern across these six assertions consistently points to greater muscle mass following intervention. However, we want to be clear: this is not proof that myostatin blockers cause muscle growth in all cases. The evidence we’ve reviewed is limited to six assertions, and we don’t have details on study design, sample sizes, or long-term outcomes. There’s also no information on side effects, safety, or whether the muscle gains are lasting. At this point, the pattern is consistent, but the body of evidence is still small and not fully detailed. We can’t say how reliable or applicable these findings are across different people, ages, or health conditions. More research with clear methods and controls would help us understand this better. If you’re considering a myostatin-targeting product, the current data suggests muscle growth may be possible—but it’s too early to know how safe, effective, or practical it is for everyday use.